P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience
ECCO'20 Vienna
2020
P504 Remote cannabis-therapy management platform for IBD patients: performance assessment
ECCO'20 Vienna
2020
P506 Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF
ECCO'20 Vienna
2020
P509 Vedolizumab levels in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease
ECCO'20 Vienna
2020
P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data
ECCO'20 Vienna
2020
P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial
ECCO'20 Vienna
2020
P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
ECCO'20 Vienna
2020
P514 Does faecal diversion induce clinical response for Crohn’s disease of the colorectum?
ECCO'20 Vienna
2020
P515 Comparability of upadacitinib pharmacokinetics in Japanese and non-Japanese subjects with ulcerative colitis with the extended-release formulation
ECCO'20 Vienna
2020
P516 Daily consumers of drip-filtered coffee have a decreased risk of developing late-onset Crohn’s disease
ECCO'20 Vienna
2020
P517 A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn’s disease
ECCO'20 Vienna
2020
P518 Ulcerative colitis drug development success rates are higher than the industry average
ECCO'20 Vienna
2020
P519 Higher anti-TNF α trough levels are not associated with increased radiological response in perianal fistulising Crohn’s disease: A multicentre study
ECCO'20 Vienna
2020